EUCTR2019-001575-37-DE
Active, not recruiting
Phase 1
ong-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311
ConditionsAdult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
DrugsBlincyto
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Adult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemia
- Sponsor
- Amgen Inc.
- Enrollment
- 108
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients that were alive at the last follow\-up and still participating in the Phase III Study 00103311\.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 80
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 28
Exclusion Criteria
- •not applicable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
ong-term follow-up of adult patients previously enrolled in Study 00103311 with a type of acute lymphoblastic leukemia that did not respond to previous therapy or that relapsed after initially successful previous therapyAdult patients with relapsed and/or refractory B-precursor acute lymphoblastic leukaemialastic leukaemiaMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-001575-37-ITAMGEN INC.75
Active, not recruiting
Phase 3
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and Blinatumomab, a specific monoclonal antibody, in adult patients, compared to the administration of chemotherapy and Imatinib. ALL28202023-508968-30-00Fondazione Gimema Franco Mandelli Onlus236
Active, not recruiting
Phase 1
ational Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategyational Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented StrategyTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-000383-18-ITG.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto204
Active, not recruiting
Phase 1
ot applicableSpinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-002611-26-ITAVEXIS, INC.308
Active, not recruiting
Phase 1
/ASpinal Muscular AtrophyMedDRA version: 20.0Level: LLTClassification code: 10079413Term: Spinal muscular atrophy type I Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10079415Term: Spinal muscular atrophy type III Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10079416Term: Spinal muscular atrophy type II Class: 10010331Therapeutic area: Diseases [C] - Nervous System Diseases [C10]CTIS2024-513086-39-00ovartis Pharma AG131